Where does Johannes Fruehauf work?

Johannes Fruehauf is General Partner at Mission Biocapital and Board director at Quralis.

What check size does Johannes Fruehauf write?

Johannes Fruehauf typically writes checks of $500K.

What boards does Johannes Fruehauf sit on?

Johannes Fruehauf holds tracked board seats at Quralis, Vaxess Technologies, Inc..

Where did Johannes Fruehauf go to school?

Johannes Fruehauf studied at Harvard Medical School (Postdoc, Molecular Biology); SLP Boston 2012 (Fellow, Entrepreneurship/Entrepreneurial Studies); Goethe University Frankfurt (MD, Medicine).

Johannes Fruehauf

Investor

General Partner at Mission Biocapital · Board director at Quralis

Cambridge, Massachusetts

Writes $500K checks · typically $1.5M

About

Johannes Fruehauf is a physician‑scientist with clinical experience in Europe and Africa, giving him a global healthcare perspective, and a serial biotech founder who built the LabCentral/BioLabs network supporting early-stage biotech.

Contact· self-published, not guessed

j•••@bio-innovation.comreveal

Invests in

AgTechBiotechFoodTechHealthtechMedical DevicesNew Materials

Board director at Quralis

Intro paths

→

In turn, Johannes can intro founders to Quralis's investors below.

Quralis's investors · 14

Amgen VenturesThousand Oaks · $1M – $3M checks · since 2023 Dementia Discovery FundLondon · since 2023 Dolby Family VenturesSan Francisco · since 2023 Droia VenturesLeuven · $540K checks · since 2025 EQT Life SciencesLuxembourg · $11M – $66M checks · since 2023 InkefAmsterdam · since 2023 MC Healthcare VenturesCambridge Mission Bay CapitalSan Francisco · since 2023 Mission BiocapitalSan Francisco · $500K checks · since 2025 Mitsui Global InvestmentMenlo Park · $500K – $10M checks · since 2023 Polaris PartnersBoston · $500K – $5M checks · since 2025 Sanofi VenturesCambridge · $5M checks · since 2023 SV Health InvestorsBoston · $1M – $20M checks SynconaLondon · since 2022

Co-founders at Quralis

Kevin EgganCo-founder

RoetCo-founder

WoolfCo-founder

Kasper RoetDirector, Executive Officer, Promoter

Experience

LabCentralFounder and Chairmancurrent2025 — presentKendall Square, Cambridge
LabCentralFounder and President/CEO2012 — 2025
Mission BioCapitalGeneral Partner, Co-Foundercurrent2011 — presentGreater Boston Area
BioLabsPresident & CEO, Foundercurrent2009 — present
Zag BioInvestor and Board Membercurrent2023 — present
Volnay TherapeuticsFounder, President, Member of the Boardcurrent2022 — presentBoston and Europe
QurAlisBoard Membercurrent2018 — presentCambridge, MA
Vaxess TechnologiesBoard Member2016 — 2025
Arkuda TherapeuticsInvestor and Board Member2019 — 2025Watertown, Massachusetts, United States
Tidal TherapeuticsFounding Investor and Board Director2018 — 2021Cambridge, MA
TotientFounding Investor and Observer2018 — 2021Cambridge, Massachusetts, United States
Sentien Biotechnologies, Inc.Board Director2016 — 2021Cambridge, MA
Pandion TherapeuticsInvestor and Board Observer2018 — 2020Cambridge MA
Mitokinin IncBoard Director2017 — 2018NYC/SF
ViThera PharmaceuticalsFounder, Chairman2011 — 2015Cambridge, MA
Aura BiosciencesVice President, Research and Development2009 — 2011
Cequent Pharmaceuticals (now Marina Biotech NASDAQ: MRNA)Vice President, Medical Affairs (Consultant)2009 — 2010
Cequent Pharmaceuticals (now Marina Biotech NASDAQ: MRNA)Vice President, Research2006 — 2010Cambridge, MA
Cequent Pharmaceuticals (now Marina Biotech NASDAQ: MRNA)Director, Preclinical and Clinical Development2006 — 2007
BIDMC/Harvard Medical SchoolSenior Research Fellow2004 — 2007
BIDMC/Harvard Medical SchoolPostdoctoral Fellow2002 — 2004
University Hospital Mannheim (Germany)Residency in OB/GYN1999 — 2002
Klinikum Hanau (Germany)Physician - Internal Medicine (18 months)1997 — 1999

Skills & more

Drug Discovery62Biotechnology95Lifesciences46Clinical Development18Cancer8Clinical Trials13Technology Transfer42In Vivo10Assay Development14Drug Delivery6Start-ups37Entrepreneurship21

+12 more

Molecular BiologyVenture CapitalHealthcareDrug DevelopmentBiochemistryCommercializationPharmaceuticsBiopharmaceuticalsPharmaceutical IndustryINDStrategyCell Biology

Languages English · French · German

From Johannes's professional profile.

Deals · 1

Vaxess Technologies, Inc.Board seat

via Mission Biocapital · filed Mar 2021 · $2M raise

Attribution from SEC filings, press coverage, and firm rosters.

Other disclosed investments

Board seats

Quralis

Per SEC Form D filings.

Colleagues at Mission Biocapital

Cassidy Blundell

Partner at Mission Biocapital

Chaya Patel

Principal at Mission Biocapital

Chris Carlin

Chief Operations Officer and Chief Compliance Officer at Mission Biocapital

Clay Rowland

Investment Associate at Mission Biocapital

Douglas Crawford

Managing General Partner at Mission Biocapital

Jennifer Griffin

Partner at Mission Biocapital

Josephine Brysting

Investment Analyst at Mission Biocapital

Linda Eng

Director of Operations, Bay Area at Mission Biocapital

Network3

Cassidy Blundell

Partner at Mission Biocapital

Chaya Patel

Principal at Mission Biocapital

Douglas Crawford

Managing General Partner at Mission Biocapital

Investors connected to Johannes in public investor directories — a warm-intro map.

Frequently asked questions

Who is Johannes Fruehauf?: Johannes Fruehauf is a physician‑scientist with clinical experience in Europe and Africa, giving him a global healthcare perspective, and a serial biotech founder who built the LabCentral/BioLabs network supporting early-stage biotech.
Where does Johannes Fruehauf work?: Johannes Fruehauf is General Partner at Mission Biocapital and Board director at Quralis.
What does Johannes Fruehauf invest in?: Johannes Fruehauf invests in AgTech, Biotech, FoodTech, Healthtech, Medical Devices, New Materials.
What check size does Johannes Fruehauf write?: Johannes Fruehauf typically writes checks of $500K.
What boards does Johannes Fruehauf sit on?: Johannes Fruehauf holds tracked board seats at Quralis, Vaxess Technologies, Inc..
Where did Johannes Fruehauf go to school?: Johannes Fruehauf studied at Harvard Medical School (Postdoc, Molecular Biology); SLP Boston 2012 (Fellow, Entrepreneurship/Entrepreneurial Studies); Goethe University Frankfurt (MD, Medicine).

Same school

Also attended Harvard Medical School180

Niko BonatsosVerdict Capital founder and pre-consensus investor formerly at General Catalyst Anthony PhilippakisInvestor at GV (Google Ventures)Ben RobbinsInvestor at GV (Google Ventures)David ReshefInvestor at GV (Google Ventures)Krishna YeshwantInvestor at GV (Google Ventures)Morgan CheathamPartner and Head of Healthcare and Life Sciences at Breyer Capital

+ 174 more

Also attended Goethe University Frankfurt68

Marcel HollerbachInvestor at Cavalry Ventures Daniel von DevivereVenture Scout at Storm Ventures Leonard LangAssociate at Blockwall Oliver ManojlovicVP Sales at Personio at PICUS CAPITAL Said HaschemiInvestor at HV Capital Ziaf RehmanAssociate at Delin Ventures

+ 62 more

Also attended University of Montpellier18

Emma Veron-DurandLegal Counsel at OneRagtime Patrick SayerGodfather at OneRagtime Matt TurckPartner at FirstMark Capital Yann DurandInvestor at MyWay Family Office Olivier ThoralCEO at Atalante Olga AristeidouRegional media contact (Greece, Cyprus) at EBRD

+ 12 more

Shared employers

Also worked at BioLabs2

Taruho KurodaImpact Partner at Fresco Capital James EllisInvestor at Clean Energy Venture

Also worked at QurAlis10

Caroline PinkneyInvestor at E12 Venture Capital, Llc Sudhir AgrawalInvestor at 82VS MegInvestor at Sanofi Ventures Jeffrey MoorePresident at MC Healthcare Ventures Miles GersonPartner at Dementia Discovery Fund Romain TouyéInvestor Relations Analyst at MBO+

+ 4 more

Also worked at Vaxess Technologies2

Aaron SandoskiMCF Partner at SV Health Investors Charlie WilsonDirector of AI and Data Analytics at Paladin Capital Group

Also worked at Aura Biosciences2

Alan WaltsVenture Partner at Advent Life Sciences Teresa BitettiPresident, Global Oncology Business Unit at Takeda Ventures